Dec 07, 2020
Biocytogen Enters into RenMab(TM)/RenLite(TM) Licensing Agreement with Xencor
Jun 15, 2020
Applied BioMath, LLC Announces Two-year Strategic Partnership with Xencor, Inc.
Feb 25, 2019
Xencor Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 20, 2019
Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045
Feb 05, 2019
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
Dec 03, 2018
Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
Nov 08, 2018
Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors
Nov 05, 2018
Xencor Reports Third Quarter 2018 Financial Results
Oct 29, 2018
Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018
Oct 05, 2018
Xencor Announces Topline Results from Phase 2 Study of XmAb®5871 in Systemic Lupus Erythematosus and Selection of Late-Breaking Abstract for Presentation at the 2018 ACR Annual Meeting
Sep 25, 2018
Xencor to Participate in Upcoming Investor Conferences
Aug 06, 2018
Xencor Reports Second Quarter 2018 Financial Results
Jul 30, 2018
Xencor to Host Second Quarter 2018 Financial Results Webcast and Conference Call on August 6, 2018
Jul 12, 2018
Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
May 07, 2018
Xencor Reports First Quarter 2018 Financial Results
May 02, 2018
Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference
Apr 30, 2018
Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018
Apr 18, 2018
Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting
Mar 21, 2018
Xencor to Present at 17th Annual Needham Healthcare Conference
Mar 20, 2018
Xencor Announces Pricing of Public Offering of Common Stock